ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of anemia prior to catheter ablation for atrial fibrillation on clinical outcomes: a U.S. retrospective cohort analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) ablation is a class I recommendation for patients with heart failure (HF) and reduced ejection fraction (HFrEF). However, data regarding the efficacy of catheter ablation in patients with heart failure and preserved ejection fraction (HFpEF) is limited. We aim to evaluate the impact of catheter ablation in patients with HFpEF compared to those with HFrEF.
methodsWe conducted a retrospective analysis using the TriNetX database from January 2016 to July 2022. Patients aged 18 years or older with AF and HF undergoing their first catheter ablation were included. Based on all baseline characteristics, propensity score matching (PSM) (1:1) was performed. The primary outcomes were the recurrence of AF, acute heart failure, and all-cause mortality over a 3-year follow-up.
resultsOur study included 4771 patients with HFpEF and 5663 patients with HFrEF. After PSM, there were 2893 patients in each group. There was no significant difference between HFpEF and HFrEF in AF recurrence (HR, 1.045; 95% CI [0.971, 1.124], Log-rank p = 0.243), acute heart failure (HR, 1.001; 95% CI [0.905, 1.108], Log-rank p = 0.982), and all-cause mortality (HR, 0.915; 95% CI [0.760, 1.101], Log-rank p = 0.346). However, HFpEF was significantly associated with an increased risk of ischemic stroke/transient ischemic attack (TIA) (HR, 1.255; 95% CI [1.061, 1.483], Log-rank p = 0.008), bleeding complications (HR, 1.287; 95% CI [1.099, 1.508], Log-rank p = 0.002), acute kidney injury (HR, 1.199; 95% CI [1.070, 1.342], Log-rank p = 0.002), pericardial complications (HR, 1.304; 95% CI [1.102, 1.542], Log-rank p = 0.002), brain natriuretic peptide (BNP) ≥ 150 pg/mL (HR, 1.185; 95% CI [1.046, 1.342], Log-rank p = 0.008), and all-cause hospitalizations (HR, 1.184; 95% CI [1.088, 1.288], Log-rank p < 0.001). In contrast, HFrEF was significantly associated with an increased risk of cardiac-related hemodynamic instability (HR, 0.725; 95% CI [0.574, 0.915], Log-rank p = 0.007).
conclusionThere was no significant difference between HFpEF and HFrEF in AF recurrence, acute heart failure, and all-cause mortality after catheter ablation. However, HFpEF was significantly associated with an increased risk of ischemic stroke/TIA, bleeding complications, acute kidney injury, pericardial complications, BNP ≥ 150 pg/mL, and all-cause hospitalizations. Conversely, HFrEF was significantly associated with an increased risk of cardiac-related hemodynamic instability.
Indexed as
Identifiers
41405663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.